Valuation: AIT Therapeutics Inc

Market Cap 6.43M 5.64M 5.19M 4.84M 9.13M 611M 9.31M 62.46M 24.2M 300M 24.13M 23.6M 1.04B P/E 2025
-0.4x
P/E 2026 -0.17x
Enterprise Value 18.17M 15.95M 14.68M 13.68M 25.8M 1.73B 26.33M 177M 68.43M 848M 68.22M 66.74M 2.95B EV / Sales 2025
7.78x
EV / Sales 2026 2.48x
Free-Float
96.64%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer 61 2026-03-26
Director of Finance/CFO 53 2026-01-04
Chief Tech/Sci/R&D Officer - 2024-03-31
Director TitleAgeSince
Director/Board Member 58 2017-08-09
Director/Board Member 54 2018-01-01
Director/Board Member 65 2018-08-12
Change 5-day change 1-year change 3-year change Capi.($)
+3.17%+20.00% - - 6.43M
+1.44%+1.53%-32.58%-14.32% 158B
+1.36%-1.18%-10.78%-9.13% 100B
+1.73%+1.22%-2.51%+50.81% 55.06B
-0.17%-2.19%+51.01%+51.71% 53.4B
+0.95%+3.13%-14.22%-41.81% 41.7B
+5.72%+15.38% - - 33.35B
+2.20%-1.42%-17.73%-45.87% 25.99B
+1.47%+6.56%+63.09%-4.12% 25.36B
+0.87%+2.38%-12.59%-3.21% 20.52B
Average +1.84%+3.07%+2.96%-1.99% 57.06B
Weighted average by Cap. +1.52%+1.38%-6.98%-1.51%

Financials

2025 2026
Net sales 3.7M 3.25M 2.99M 2.79M 5.26M 352M 5.37M 36.01M 13.95M 173M 13.91M 13.61M 602M 7.68M 6.74M 6.21M 5.78M 10.91M 730M 11.13M 74.64M 28.92M 358M 28.83M 28.21M 1.25B
Net income -46.62M -40.94M -37.68M -35.11M -66.22M -4.43B -67.56M -453M -176M -2.18B -175M -171M -7.57B -33.25M -29.19M -26.87M -25.04M -47.22M -3.16B -48.18M -323M -125M -1.55B -125M -122M -5.4B
Net Debt 4.77M 4.19M 3.86M 3.59M 6.78M 454M 6.91M 46.38M 17.97M 223M 17.91M 17.53M 775M 11.74M 10.31M 9.49M 8.84M 16.68M 1.12B 17.02M 114M 44.23M 548M 44.09M 43.14M 1.91B
Logo AIT Therapeutics Inc
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
Employees
-